

19 Dec 2016 |

Top Alliance Of 2016: Cast Your Vote!

by **Nancy Dvorin**

It's time once again for **In Vivo's Deal of the Year** contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to [pick the winners](#). (It's free.)

In Vivo's Top Alliance Of 2016 – The Nominees Are:

Synthetic Bio Tie-Up: Synlogic received big pharma validation of its technology in early February, signing its first-ever partnership, a multiyear collaboration with [AbbVie Inc.](#) to develop "synthetic biotic" therapies for Crohn's disease and ulcerative colitis. [\[See Deal\]](#)

Cigna Pays If PCSK9s Perform: In May, [Cigna Corp.](#) signed value-based contracts with [Amgen Inc.](#) and [Sanofi/Regeneron Pharmaceuticals Inc.](#) for their cholesterol-lowering drugs *Repatha* and *Praluent*. The drug makers will discount the products more steeply if LDL levels don't drop. (Also see "[Cigna's Bradbury Talks PCSK9 Contracts And Value Versus Volume](#)" - Pink Sheet, 11 May, 2016.)

Verily We Roll Along: Google-owned [Verily Life Sciences](#) formed diabetes and neuromodulation joint ventures with big pharmas [GlaxoSmithKline PLC](#) (August) and Sanofi (September). [\[See Deal\]](#)[\[See Deal\]](#)

AstraZeneca Drops Assets: In October, AstraZeneca PLC completed five out-licensing deals cumulatively worth more than \$1bn, the busiest month by far in its year-long purge of non-core assets. [\[See Deal\]](#)[\[See Deal\]](#)[\[See Deal\]](#)[\[See Deal\]](#)[\[See Deal\]](#)

Bayer Buys Into Gene Editing: In August, [Bayer AG](#) and [CRISPR Therapeutics AG](#) unveiled their \$335m joint venture [Casebia Therapeutics](#), which will use CRISPR's gene editing technology to develop drugs for blood disorders, blindness and congenital heart disease. [\[See Deal\]](#)

[CLICK HERE Here To Cast Your Vote For The Most Significant Strategic Alliance Of 2016](#)

Coming Up Next In IVDOTY16: Top Financing And Top M&A
